Alvotech rises as UK clears new arthritis drug
06/11/2025 14:40
** Shares of biotech firm Alvotech ALVO.O rise 2.4% to $5 during early trading ** ALVO, along with private co Advanz Pharma, says UK medicines regulator has approved Gobivaz, a biosimilar to Johnson & Johnson's JNJ.N Simponi for immune-related conditions including rheumatoid arthritis and ulcerative colitis ** Gobivaz will be available in two strengths and in both pre-filled syringe and autoinjector formats, co says ** Alvotech develops and supplies the drug, while Advanz Pharma holds exclusive rights to market it in Europe and UK, says ALVO ** Including session's move, stock down ~63% (Reporting by Sahil Pandey in Bengaluru) ((Sahil.Pandey@thomsonreuters.com))
Recent news on Alvotech SA
See all newsBrief: CMS Announces Selection Of Drugs For Third Cycle Of The Medicare Drug Price Negotiation Program
Brief: Alvotech and Teva Secure U.S. Settlement Date For AVT06
India's Dr Reddy's rises after EU marketing authorisation for osteoporosis biosimilar
Brief: UK High Court Rules In Favor Of Alvotech Paving Way For AVT06, Biosimilar To Eylea
U.S. STOCKS ON THE MOVE-Cummins, EPAM Systems, Qualcomm